

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Glow LifeTech Corp. (the "Issuer").

Trading Symbol: GLOW

Number of Outstanding Listed Securities: 56,278,546

Date: May 4, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. **Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.**

Glow LifeTech is a Canadian-based biotechnology company focused on producing nutraceutical and cannabinoid-based products with dramatically enhanced bioavailability, absorption and effectiveness. Glow LifeTech has rights to the ground breaking, plant-based MyCell Technology® delivery system, which transforms poorly absorbed natural compounds into enhanced water-compatible concentrates, unlocking the full healing potential of natural active compounds.

2. **Provide a general overview and discussion of the activities of management.**

Management continued to be involved in the development of its business as more specifically detailed in 1 above.

In addition, one of Glow's licensed products ArtemiC™ was submitted to Health Canada's Natural and Non-prescription Health Products Directorate (NNHPD) on Mar 11, 2021. The application, which is currently under review by Health Canada, included ArtemiC™ supporting COVID-19 Phase II clinical trial results. Under Canadian regulations, all NHPs must obtain premarket approval by Health Canada to assure they are safe, effective and of high quality before being allowed to be sold in Canada. Once Health Canada makes this assessment, they are issued a Natural Product Number (NPN).

3. **Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.**

Management continued to be involved in the development of its business and product launches as more specifically detailed in 1 above.

4. **Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.**

None in the month of April 2021.

5. **Report on any labour disputes and resolutions of those disputes if applicable.**

None in the month of April 2021.

6. **Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.**

None in the month of April 2021.

- 7. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.**

None in the month of April 2021.

- 8. Provide details of any securities issued and options or warrants granted.**

None in the month of April 2021.

- 9. Provide details of any loans to or by Related Persons.**

None in the month of April 2021.

- 10. Provide details of any changes in directors, officers or committee members.**

None in the month of April 2021.

- 11. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.**

On March 12, 2020, the World Health Organization ("WHO") declared a global pandemic as a result of the COVID-19 virus. The impacts on global commerce are expected to be far reaching and, at this point, unknown. The global lock-down impacts have negatively impacted the economy as a whole and capital markets in Canada. The effects on the Company's operations have been minor to date but management continues to monitor and contingency plan.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 4, 2021.

Clark Kent

Name of Director or Senior Officer

"W. Clark Kent"

Signature

President & Chief Executive Officer

Official Capacity

Issuer Details Name of Issuer Relay Medical Corp.	For Month End April 30, 2021	Date of Report YY/MM/D 2021/05/04
Issuer Address 65 International Blvd. Suite 206		
City/Province/Postal Code Toronto, ON M9W 6L9	Issuer Fax No. 1-844-247-6633	Issuer Telephone No. 647-872-9982
Contact Name W. Clark Kent	Contact Position President	Contact Telephone No. 647-872-9982
Contact Email Address ckent@glowlifetech.com	Web Site Address https://www.glowlifetech.com/	